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Abstract
Background: Multiple sclerosis (MS) patients with breakthrough disease on immunomodulatory drugs are frequently
offered to switch to natalizumab or immunosuppressants. The effect of natalizumab monotherapy in patients with
breakthrough disease is unknown.
Methods: This is an open-label retrospective cohort study of 993 patients seen at least four times at the University of
California San Francisco MS Center, 95 had breakthrough disease on first-line therapy (60 patients switched to natalizumab,
22 to immunosuppressants and 13 declined the switch [non-switchers]). We used Poisson regression adjusted for potential
confounders to compare the relapse rate within and across groups before and after the switch.
Results: In the within-group analyses, the relapse rate decreased by 70% (95% CI 50,82%; p,0.001) in switchers to
natalizumab and by 77% (95% CI 59,87%; p,0.001) in switchers to immunosuppressants; relapse rate in non-switchers did
not decrease (6%, p=0.87). Relative to the reduction among non-switchers, the relapse rate was reduced by 68% among
natalizumab switchers (95% CI 19,87%; p=0.017) and by 76% among the immunosuppressant switchers (95% CI 36,91%;
p=0.004).
Conclusions: Switching to natalizumab or immunosuppressants in patients with breakthrough disease is effective in
reducing clinical activity of relapsing MS. The magnitude of the effect and the risk-benefit ratio should be evaluated in
randomized clinical trials and prospective cohort studies.
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Introduction
It has become common in daily practice for patients with
relapsing forms of multiple sclerosis (MS) who have breakthrough
disease on first-line disease-modifying therapy (DMT) (interferon-
beta and glatiramer acetate) to switch to other agents. Before
natalizumab was available, broad-spectrum immunosuppressants
such as cyclophosphamide, mitoxantrone, methotrexate and
mycophenolate mofetil (hereafter grouped together and referred
to as ‘‘immunosuppressants’’) were often used as second-line
therapies. With the re-introduction of natalizumab to the market
in 2006 for patients with MS [1,2], options for treating
breakthrough disease have expanded to include switching to
another first-line DMT, to an immunosuppressant, or to
natalizumab. While previous studies have provided a rationale
for switching to another therapy in breakthrough disease, none has
evaluated the efficacy of switching to second-line monotherapy
versus controls in this context [3,4,5,6].
Our aim was to compare the clinical effects of three treatment
strategies in patients with breakthrough disease: i) switching to
natalizumab, ii) switching to an immunosuppressant, or iii)
remaining on or discontinuing first–line treatment.
Materials and Methods
Patients’ characteristics
A systematic chart review of 993 patients seen at least four times
at the University of California San Francisco (UCSF) MS Center
from November 2005 to November 2008 was performed by a
single neurologist (TCT) to identify patients with relapsing-
remitting (RR) or relapsing secondary progressive (SP) MS [7]
whose physicians recommended a switch to second-line therapy
due to breakthrough disease despite at least six months on first-line
DMT [8]. Among these patients, we identified three groups: i)
patients who switched to natalizumab (natalizumab group), ii)
patients who switched to an immunosuppressant (immunosup-
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did not start the treatment, typically due to insurance constraints
or fear of adverse effects (non-switchers). We also queried the
UCSF MS Center database from 2002 (date of database
availability) onward, to identify patients who switched to
immunosuppressants. In all groups, the definition of breakthrough
disease and the decision to recommend a switch was made by each
patient’s UCSF MS Center neurologist.
The date of the switch was defined as the date when the second-
line therapy was started (for the natalizumab or immunosuppres-
sant switchers) or the date when the switch was proposed (for the
non-switchers). Annualized relapse rates were calculated for all
patients in the last year on DMT and during the entire follow-up
period.
For all patients, at least three months of follow-up after the
proposed switch were required. Patients who switched to second-
line therapy due to poor tolerability of first-line DMT were
excluded from the study. Patients for whom meaningful con-
founders (such as EDSS at the time of the switch) were missing
were excluded.
Relapse was defined as the development of new or recurrent
neurological symptoms not associated with fever or infection
lasting for at least 24 hours and accompanied by new neurological
signs, following a period of symptomatic stability of 30 days [7].
Pseudoexacerbations were excluded.
This study was approved by the UCSF Committee on Human
Research (CHR). As the data were extracted from a clinical
database used for all patients seen at the MS clinic, authors
weren’t required to ask for written consent as they had a waiver of
consent from UCSF CHR.
Statistical Analyses
Characteristics of the three groups at the time of switch were
compared using ANOVA, Kruskal-Wallis, chi-square or Fisher’s
exact tests, as appropriate. A Poisson regression model was used to
compare relapse rates. Differences in the length of follow-up were
accommodated using so-called offsets, while within-person corre-
lation of relapse rates in the periods before and after switching
were accounted for using a normally-distributed random intercept.
The effect of switching to natalizumab or immunosuppressants
was captured by interactions of the post-switch treatment with the
period (post- vs pre-switch). We identified age, gender, race, EDSS
at the time of the switch (baseline EDSS), disease duration,
number of first-line DMTs received and time on first-line DMT
before the switch as potential confounders of the effects of the
treatment received after failure of first-line DMT. Accordingly, we
adjusted both for the main effects of these variables, which capture
their effects on the pre-switch relapse rate, as well as their interactions
with the period, which capture their effects on reductions in the relapse
rate after switching. We modeled non-linearities in the effects of
disease duration and time on first-line DMT using restricted cubic
splines. The regression analysis excluded four patients with missing
baseline EDSS scores. Because the sample size was limited, in
particular for non-switchers, we removed covariates from the full
model with p-values .0.25. The main statistical analyses were
performed using the xtpoisson command in STATA Version 10.0
(StataCorp, College Station, TX).
Results
Patients’ characteristics
The details regarding the inclusion or exclusion of reviewed
charts are provided in Figure 1. We identified 99 patients; for the
95 who had complete data, characteristics at the time of switch are
provided in Table 1. Within this group, 60 switched to
natalizumab, 22 switched to immunosuppressants, and 13 were
non-switchers (eight remained on the same DMT, one switched to
another first-line DMT and four stopped treatment). The number
of and time on first-line DMT before the switch, EDSS and
percentage of those with relapsing SPMS at the time of switch, and
years of follow-up after the switch differed between the groups at
baseline. These results were not meaningfully changed when the
four patients with missing EDSS measures were included.
In the study 60 patients received more than one first-line DMT
before the switch and 35 received only one: 63 patients received
Avonex, 28 patients received Betaseron, 40 received Rebif and 43
received Copaxone.
Relapse rate reductions
In the pre-switch period, relapse rates were similar across the
three groups (p=0.71), after adjustment for covariates, including
during the last year (data not shown). In the post-switch period, the
relapse rate was reduced both among natalizumab (70%, 95%CI
50, 82%, p,0.001) and immunosuppressant switchers (77%, 95%
CI 59, 87%, p,0.001) but was not substantially reduced among
the non-switchers (6%, 95% CI -99, 56%, p=0.87) (Table 2).
After adjustment for the effects of covariates on reductions in the
relapse rate, switching had an overall positive effect on clinical
activity (p=0.01 for heterogeneity). In pair-wise comparisons with
non-switchers, the net reduction in the relapse rate was 68%
among natalizumab switchers (95% CI 19, 87%, p=0.017) and
76% among immunosuppressant switchers (95% CI 36, 91%,
p=0.004). Finally, those who were switched to immunosuppres-
sants had a 24% reduction in the relapse rate when compared to
those who switched to natalizumab (p=0.49). Figure 2 represents
the effect of the switch on the relapse rate for each group.
The percentage of patients who remained relapse-free after the
switch was 53.8% for the non-switchers, 74.2% for the
natalizumab group and 50% for the immunosuppressants group
which had the longest follow-up after the switch (p=0.06).
The analyses were repeated considering the type of disease
(SPMS vs. RRMS). For the RRMS patients the within group
reduction in the relapse rate was 60% (95%CI 33, 76%, p,0.001)
for natalizumab and 78% (95%CI 50, 91%) for immunosuppres-
sant group, while the reduction in the non-switchers was not
significant (14%, 95%CI -80, 67%, p=0.76). Comparing
natalizumab to the non-switchers we observed a reduction in the
relapse rate of 54% (95%CI -62, 84%, p=0.17) and in the
comparison between immunosuppressant switchers and non-
switchers, a reduction of 75% was observed for immunosuppres-
sant switchers (95%CI 7,93%, p=0.038). Immunosuppressant
switchers had a reduction in the relapse rate compared to
natalizumab, although this difference was not statistically signif-
icant (46%, 95%CI -58,79%, p=0.21). For the SPMS patients
there was a reduction in the relapse rate of 97% (95% CI 62,99%,
p=0.007) after the switch to natalizumab treatment and of 83%
after the switch to immunosuppressant treatment (95%CI 35,95%,
p=0.01). Relapse rate reduction in the non-switchers was 6%
(p=0.96). When comparing natalizumab to the non-switchers,
there was a reduction of 97% (p=0.024) and comparing the
immunosuppressants to the non-switchers, the reduction was 82%
(p=0.11).
There was a higher proportion of patients treated with IFN-b
(61.5% for the non-switchers group, 70% for the natalizumab and
90.9% in the immunosuppressant switchers) than other first-line
treatment. We studied the effect of switching in patients who
switched from any IFN-b and in those switching from GA. In the
IFN-b group, switching to natalizumab was associated with a
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and switching to immunosuppressants reduced the relapse rate by
80% (95%CI 61,90%, p,0.001). In this case, the non-switchers
had an increase in the relapse rate of 4%, although this difference
was not statistically significant (p=0.93). Comparing the natali-
zumab group to the non-switchers, natalizumab reduced the
relapse rate by 76% (95%CI 21, 92%, p=0.018). Immunosup-
pressants reduced the relapse rate by 80% (95%CI 42, 93%,
p=0.003) when comparing to the non-switchers. There were no
differences between immunosuppressant and natalizumab switch-
ers (IRR 0.8, 95%CI 0.31, 2.02, p=0.63).
There were only 25 patients who switched from GA to a
second-line MS agents. In those patients previously treated with
GA, the switch to natalizumab reduced the relapse rate by 63%
(95% CI 15, 84%, p=0.019) while the switch to immunosuppres-
sant was associated with an increase in the relapse rate by 8%
(IRR 1.08, 95% 0.17,6.88, p=0.94). As this group was small, 95%
CI are large.
Discussion
In this study of 95 patients with breakthrough relapsing MS on
first-line DMTs, we found that switching to either natalizumab or
immunosuppressant achieved large net reductions in the relapse
rate. The reduction in the relapse rate among the natalizumab
switchers was similar in magnitude to the effect size reported in the
pivotal trial of natalizumab monotherapy, in which the annualized
relapse rate was reduced by 68% compared to placebo [2].
Reported rates of relapse reduction in both the mitoxantrone and
cyclophosphamide trials were 63% compared to the control
groups in the first year [9,10]. However, these studies included
greater proportion patients with SPMS or who received
combination therapy.
Although immunosuppressants and natalizumab had a similar
impact on reducing the relapse rate in our study, the exposure to
strong immunosuppressants may be associated with an increased
risk of serious infection or secondary neoplasm [11,12] or, in the
Figure 1. Diagram of charts reviewed. Diagram showing the total number of charts reviewed, the reason for exclusion and all included patients
in the study. For those patients who switched to immunosuppressants, a detail of the immunosuppressant agents used is provided and for the non-
switchers further detail is presented. *From the 99 identified patients, 4 were excluded from the statistical analyses due to missing information for
important baseline characteristics.
doi:10.1371/journal.pone.0016664.g001
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risks associated with natalizumab, particularly that of progressive
multifocal leukoencephalopathy, such adverse events appear to be
fairly infrequent [14,15]. Some clinicians have considered the use
of drug holidays to reduce the risk of developing PML. However
this interruption might lead to a return of clinical flares and
radiologic activity [16] or at least to the pre-treatment level of
disease activity [17]. Active monitoring of patients receiving
natalizumab by regular MRI scanning, careful assessment of new
MRI lesions or symptoms and, when necessary, CSF analysis is
crucial for detecting JC virus infection. Treatment with plasma
exchange (PLEX) followed by steroids when there is neurologic
progression due to an immune reconstitution inflammatory
syndrome (IRIS) is considered the treatment of choice after the
diagnosis of PML, although there are no clinical trials [18].
Another question that remains unclear is whether combination
therapy is helpful and safe for patients with breakthrough disease
on the first-line DMT. Some studies have shown that the
combination of first-line and second-line therapies is effective in







Age{ 37.2 (10.8) 40.5 (10) 41.7 (10.4) 0.44
Female, % (No) 53.8 (7) 66.7 (40) 63.6 (14) 0.68
Caucasian, % (No) 69.2 (9) 73.3 (44) 77.3 (17) 0.84
Relapsing SPMS at the switch, % (No) 15.4 (2) 20 (12) 52.4 (11) 0.014
Disease duration{, years 8.9 (7.9) 11 (6.5) 11.5 (6.4) 0.5
Number of DMTs before the switch1 2 (1–3) 2 (1–3) 1 (1–3) 0.07
Years on first-line DMT before the switch{ 3.4 (1.9) 5.3 (3.3) 4.1 (2.8) 0.08
Years of follow-up after the switch{ 1.1 (0.6) 1.1 (0.6) 3.3 (2.4) ,0.001
EDSS at the time of switch1 2.5 (0–7.0) 3.0 (1.0–7.0) 4.0 (2.5–7.0) 0.01





























The annualized relapse rate (ARR) during the last year of treatment with first-line disease modifying therapy, as well as the ARR for the whole period on DMT and ARR
after the switch. The time of follow-up after the switch is also presented for each patient group. SPMS: secondary progressive multiple sclerosis. DMT: disease modifying
therapy. EDSS: expanded disability status scale.
doi:10.1371/journal.pone.0016664.t001
Figure 2. Mean annualized relapse rate before and after the
switch for each group. Bar plot showing the effect of switching
therapy on the relapse rate within group. The model is adjusted for
baseline EDSS, disease duration and time on first-line disease modifying
therapy. Bars indicate 95% CI for the mean annualized relapse rate.
Non-switchers: n=13, Natalizumab: n=60, Immunosuppressants,
n=22. * Statistically significant.
doi:10.1371/journal.pone.0016664.g002
Table 2. Effect of switching on the relapse rate measured as
incidence rate ratio (IRR), using a Poisson regression model,
after adjusting for baseline EDSS, disease duration and time
on first-line disease modifying therapy.
IRR 95% CI p-value
WITHIN GROUP COMPARISON
Non-switchers (n=13) 0.94 (0.44,1.99) 0.87
Natalizumab switchers (n=60) 0.3 (0.18,0.50) ,0.001
Immunosuppressant switchers (n=22) 0.23 (0.13,0.41) ,0.001
BETWEEN GROUPS COMPARISON
Natalizumab vs Non-switchers 0.32 (0.13,0.81) 0.017
Immunosuppressant vs Non-switchers 0.24 (0.09,0.64) 0.004
Immunosuppressant vs Natalizumab 0.76 (0.36,1.63) 0.49
Within group comparison compares the relapse rate before and after the switch
for each group. The between group comparison compares treatment effect on
immunosuppressant and natalizumab groups with non-switchers or between
natalizumab and immunosuppressants.
doi:10.1371/journal.pone.0016664.t002
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with different mechanisms of action in other diseases supports a
similar approach in MS, the evidence for doing so is limited [20].
More studies are needed to clarify the usefulness and safety of
combination therapy.
The balance in the risk/benefit ratio of natalizumab versus
immunosuppression as second-line therapy is unknown and may
be influenced not only by potential adverse effects but also by
factors such as drug- and infusion-related costs and ease of access.
While our study addresses an important clinical question, it has
some limitations. Since the treatment assignment was not
randomized, there might be differences in the groups that led to
a different response to second-line therapies. Although the model
was adjusted for all known potential confounders, there may be
important covariates for which we did not account. In addition,
since patients had breakthrough disease before the switch, it is
important to consider the possible effect of regression to the mean,
which may lead to a falsely high reduction in the relapse rate
within groups. However, the three groups had similar relapse rates
before switching both overall and in the last year on first-line
DMT, such that if disease activity was unusually high in the pre-
switch period, one would expect regression to the mean to occur in
a non-differential manner during the follow-up period. As such,
any difference between groups is likely a true effect rather than a
result of regression to the mean, which could only explain
differences within groups. Information on progression of disability
as documented by EDSS after the switch to second-line DMT was
not available for all patients.
Immunosuppressants were available before natalizumab and the
factors influencing a decision to switch may have changed over
time, leading to differences between the immunosuppressant and
natalizumab groups for which we cannot account. A further
potential problem is that the threshold for recommending a switch
may differ among our center’s neurologists, in part due to the lack
of definition of breakthrough disease. A standard definition of
breakthrough disease should be established in order to promptly
identify sub-optimal responders to first-line therapies who may
benefit from switching to second-line therapies. In our study,
breakthrough was defined clinically and/or radiologically by the
patient’s MS specialist. As recommended in the literature [21], the
monitoring strategies to evaluate DMT effectiveness at our center
included regular follow-up visits by the same neurologist, and
monitoring of relapses, disease progression by EDSS, and new T2-
bright and gadolinium-enhancing lesions on brain MRI scans. We
also excluded reasons other than breakthrough disease for
stopping first-line DMT such as poor compliance or side effects.
Besides this, patients treated with IFNB are tested for neutralizing
antibodies to IFNB when suspecting breakthrough disease and
considering a switch to another therapy [21].
While second-line therapies are more likely to be associated with
rare but serious adverse effects, our data provide strong evidence
for switching to such treatments when patients experience
breakthrough disease on first-line agents. These results do not
negate previous observations that patients may benefit from
switching from one to another first-line therapy [3,4,5]. Defining
an algorithm for the timing and indications for treatment switch
would be of great clinical utility but requires a consensus definition
of breakthrough disease.
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